Częstość zakażeń układu oddechowego u dzieci z dysplazjÄ oskrzelowo-płucnÄ otrzymujÄ cych profilaktycznie paliwizumab

1. After subsequent doses of palivizumab, statistically significant reduction is reported in the following areas: number of episodes of lower respiratory tract infections, and number of respiratory-related hospitalizations comparing the first vs fifth dose, and incidence of corticosteroid or bronchodilators administration. 2. Mortality in the analyzed population was few and none of the reported deaths were caused by RS V infection. 3. The incidence of adverse reactions was low. 4. Prophylactic administration of palivizumab was offered to children through sites located throughout the country. It was conducted in line with relevant guidelines and supports that such an intervention is effective and should take the form of a mandatory program based on an assumption that RS V infection was prevented.